The company had earlier announced about the approval received from the MHRA for Liraglutide
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
PREVENAR offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine to help protect infants and children from the 20 serotypes responsible for the majority of currently circulating pneumococcal disease in the EU and globally
Varenicline is indicated for smoking cessation in adults
VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU
The company intends to respond to the two minor observations within the stipulated time
The orphan drug designation by the EC is issued for drugs which are intended to treat diseases that affect fewer than five in 10,000 people in the European Union
This product has sales of about US$ 20 million in Europe
TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union
Subscribe To Our Newsletter & Stay Updated